309 - Prolongation of Eosinophilic Esophagitis Treatment with Budesonide Orodispersible Tablets for Incomplete Responder is Effective and Safe: Results from a 6-Weeks Open-Label Treatment Phase of the Pivotal Trial EOS-1
Alfredo J. Lucendo(Hospital General de Tomelloso), Alex Straumann(University of Zurich), Alain Schoepfer(University Hospital of Lausanne), Ralph Müeller(Dr Falk Pharma (Germany)), Michael Vieth(Bayreuth Medical Center), Stephan Miehlke, Stefan Schubert, Ulrike von Arnim, Jan Tack(KU Leuven), Albert J. Bredenoord(Amsterdam Neuroscience), Dirk Hartmann, Christoph Schlag, Stefan Brückner, Javier Molina‐Infante(Complejo Hospitalario de Cáceres), Roland Greinwald(Dr Falk Pharma (Germany)), Constanza Ciriza de los Ríos(Hospital Clínico San Carlos), Jamal Hayat, Stephen E. Attwood(Durham University), Ahmed Madisch(Technische Universität Dresden)
Cited by 3
Related Papers
Functional Gastroduodenal Disorders
|Gastroenterology|2006|2.4k
Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study
|Gastroenterology|2020|2.1k
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k